Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to crush Hard-to-Treat leukemia

NCT ID NCT07224100

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This phase II trial tests a combination of chemotherapy (DA-EPOCH) plus a targeted drug (ponatinib) in adults newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 33 people to see if this approach leads to a complete molecular response, meaning no detectable cancer cells. The goal is to improve initial treatment and reduce the chance of relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DA-EPOCH chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) with or without rituximab plus ponatinib
What this could lead to
If successful, this could offer a more effective initial treatment for Ph+ ALL, potentially leading to better remission rates and longer survival.
What could go wrong
This is an early phase II trial with only 33 participants, so results may not apply to everyone. Chemotherapy and ponatinib can cause serious side effects like infections, heart problems, and blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) lymphoblastic lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 B LYMPHOBLASTIC LEUKEMIA/LYMPHOMA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 LYMPHOBLASTIC LYMPHOMA

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.